JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB238742

Anti-ST3GAL4/STZ antibody

Be the first to review this product! Submit a review

|

(1 Publication)

Rabbit Polyclonal ST3GAL4/STZ antibody. Suitable for IHC-P and reacts with Human samples. Cited in 1 publication. Immunogen corresponding to Recombinant Fragment Protein within Human ST3GAL4 aa 1-200.

View Alternative Names

CGS23, NANTA3, SIAT4C, STZ, ST3GAL4, Gal-NAc6S, SAT-3, ST-4, ST3Gal IV, ST3GalA.2, Sialyltransferase 4C, ST3GalIV, SIAT4-C

1 Images
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-ST3GAL4/STZ antibody (AB238742)
  • IHC-P

Supplier Data

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-ST3GAL4/STZ antibody (AB238742)

Formalin-fixed, paraffin-embedded human cervical cancer tissue stained for ST3GAL4/STZ using ab238742 at 1/300 dilution in immunohistochemical analysis.

After dewaxing and hydration, antigen retrieval was mediated by high pressure in a citrate buffer (pH 6.0). Section was blocked with 10% normal goat serum 30 minutes at RT. Then primary antibody (1% BSA) was incubated at 4°C overnight. The primary is detected by a biotinylated secondary antibody and visualized using an HRP conjugated SP system.

Key facts

Host species

Rabbit

Clonality

Polyclonal

Isotype

IgG

Carrier free

No

Reacts with

Human

Applications

IHC-P

applications

Immunogen

Recombinant Fragment Protein within Human ST3GAL4 aa 1-200. The exact immunogen used to generate this antibody is proprietary information.

Q11206

style
left-column

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "IHCP" : {"fullname" : "Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections)", "shortname":"IHC-P"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Human": { "IHCP-species-checked": "testedAndGuaranteed", "IHCP-species-dilution-info": "1/200 - 1/500", "IHCP-species-notes": "<p></p>" } } }
style
left-column
style
left-column

Properties and storage information

Form
Liquid
Purification technique
Affinity purification Protein G
Purification notes
Purity greater than 95%.
Storage buffer
pH: 7.4 Preservative: 0.03% Proclin 300 Constituents: PBS, 50% Glycerol (glycerin, glycerine)
Shipped at conditions
Blue Ice
Appropriate short-term storage duration
1-2 weeks
Appropriate short-term storage conditions
+4°C
Appropriate long-term storage conditions
-20°C
Aliquoting information
Upon delivery aliquot
Storage information
Avoid freeze / thaw cycle
style
left-column

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

ST3GAL4 also known as STZ is a glycosyltransferase enzyme responsible for the addition of sialic acid to galactose-containing substrates specifically at the third carbon position of the galactose unit. This enzyme has a molecular mass of approximately 43 kDa. It is expressed mainly in the human liver pancreas and brain. By catalyzing the transfer of sialic acid ST3GAL4 influences the charge and recognition potential of glycoproteins and glycolipids on the cell surface.
Biological function summary

ST3GAL4 contributes to the synthesis of sialylated glycoconjugates which plays a significant role in cell-cell interactions signaling and immune response modulation. It is involved in the creation of the sialyl Lewis X (sLe^x) epitope an important component in selectin-mediated adhesion processes. ST3GAL4 does not function as part of a larger enzymatic complex but orchestrates critical modification of glycoconjugates on its own. Its activity affects how cells communicate and interact within the physiological environment.

Pathways

ST3GAL4 operates within the glycosylation pathway specifically influencing the N-glycan biosynthesis pathway. Its action is important for the formation of complex glycan structures on proteins and lipids influencing their stability and function. ST3GAL4 is related to other sialyltransferases such as ST3GAL1 which also contribute to the diversity of glycan structures in cells. The proper function of these pathways ensures the correct formation of glycan codes critical for cellular communication.

Aberrant activity or expression of ST3GAL4 associates with cancer and inflammatory diseases. Changes in the sialylation pattern mediated by ST3GAL4 alter cell adhesion and migration contributing to cancer metastasis and progression. In inflammatory disorders altered glycosylation can lead to abnormalities in immune cell interactions exacerbating the disease state. ST3GAL4 connects with proteins like selectin affecting cell adhesion dynamics in both oncological and inflammatory contexts.
style
left-column
style
left-column

Product protocols

For this product, it's our understanding that no specific protocols are required. You can visit:
style
left-column

Target data

A beta-galactoside alpha2-3 sialyltransferase involved in terminal sialylation of glycoproteins and glycolipids (PubMed : 8288606, PubMed : 8611500). Catalyzes the transfer of sialic acid (N-acetyl-neuraminic acid; Neu5Ac) from the nucleotide sugar donor CMP-Neu5Ac onto acceptor Galbeta-(1->3)-GalNAc- and Galbeta-(1->4)-GlcNAc-terminated glycoconjugates through an alpha2-3 linkage (PubMed : 8288606, PubMed : 8611500). Plays a major role in hemostasis. Responsible for sialylation of plasma VWF/von Willebrand factor, preventing its recognition by asialoglycoprotein receptors (ASGPR) and subsequent clearance. Regulates ASGPR-mediated clearance of platelets (By similarity). Participates in the biosynthesis of the sialyl Lewis X epitopes, both on O- and N-glycans, which are recognized by SELE/E-selectin, SELP/P-selectin and SELL/L-selectin. Essential for selectin-mediated rolling and adhesion of leukocytes during extravasation (PubMed : 25498912). Contributes to adhesion and transendothelial migration of neutrophils likely through terminal sialylation of CXCR2 (By similarity). In glycosphingolipid biosynthesis, sialylates GM1 and GA1 gangliosides to form GD1a and GM1b, respectively (PubMed : 8288606). Metabolizes brain c-series ganglioside GT1c forming GQ1c (By similarity). Synthesizes ganglioside LM1 (IV3Neu5Ac-nLc4Cer), a major structural component of peripheral nerve myelin (PubMed : 8611500).
See full target information ST3GAL4
style
left-column

Publications (1)

Recent publications for all applications. Explore the full list and refine your search

Bioengineered 12:5323-5333 PubMed34499008

2021

The tumor-suppressive effects of alpha-ketoglutarate-dependent dioxygenase FTO via N6-methyladenosine RNA methylation on bladder cancer patients.

Applications

Unspecified application

Species

Unspecified reactive species

Wenfa Yi,Yong Yu,Yafei Li,Juan Yang,Shuying Gao,Lingfen Xu
View all publications
style
left-column
style
left-column
style
right-column

Complementary Products

Secondary Antibodies

AB150077

Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488)

Immunocytochemistry/ Immunofluorescence - Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488) (AB150077)

  • 5
  • 20
Primary Antibodies

AB176689

Anti-ZNF384 antibody

Immunoprecipitation - Anti-ZNF384 antibody (AB176689)

  • 5
  • 1
Primary Antibodies

AB237050

Anti-CBWD2 antibody

Western blot - Anti-CBWD2 antibody (AB237050)

  • 0
  • 0
Primary Antibodies

AB250223

Anti-ZNF529 antibody [EPR13674] - BSA and Azide free

RabMAb|Recombinant

Western blot - Anti-ZNF529 antibody [EPR13674] - BSA and Azide free (AB250223)

  • 0
  • 0

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com